Windlas Biotech Q2FY26 Concall Decoded: – Injectables warm up, ESOPs heat up, and margins stretch like yoga day
1. Opening Hook
If pharma had an attendance award, Windlas would win it — 11 straight quarters of record revenue and not a single “missed class.” While the broader Indian pharma market crawled at 7.7%, Windlas sprinted 19% ahead, fuelled by injectables, exports, and a rather generous ESOP buffet that made analysts raise an eyebrow and employees smile wide. Investors got a dividend; employees got stock; and the CFO got to explain why the word “non-cash” suddenly sounded like a charm spell.
Spoiler: it gets spicier when the ESOP math meets EBITDA margins later. Stay tuned. 😏
2. At a Glance
Revenue up 19% YoY: Eleven quarters in a row — they’ve clearly forgotten what “flat” means.
EBITDA ₹29 cr (Q2) / ₹55 cr (H1): Execution discipline or accounting fitness regime? You decide.
PAT ₹18 cr (Q2) / ₹35 cr (H1): Margins flexed harder than expected.
Gross Margin +70 bps: Scale magic beats raw material gremlins.
EPS ₹16.91 (H1): Up 21% YoY — because growth compounds better than vitamin tablets.
Liquidity ₹237 cr: Pharma’s version of a fully stocked medicine cabinet.
Stock split? Nope. But ESOPs at ₹5? Cue jealous laughter from retail investors.
3. Management’s Key Commentary
“We delivered 19% growth despite industry volume decline.” (Translation: When the market coughed, we sold the cough syrup.)
“ESOP expenditure is an investment in people, not a cost.” (Said every CFO before analysts reached for their calculators.) 😅
“Almost 100 key employees covered under the ESOP plan.” (Translation: Everyone who can leave has now been handcuffed with shares.)
“Injectables ramping up well; customer approvals coming in.” (Still waiting for the part where it becomes profitable though.)
“Plant-6 will be commissioned within FY26.” (One more facility — because apparently five weren’t enough.)
“Exports grew 23% H1; moderation in Q2 is temporary.” (Read: We’ll blame customs clearance delays if needed.)
“We are open to inorganic expansion — but not to buying trouble.” (Sensible — nobody wants to inherit someone else’s FDA nightmares.) 😏
